Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. (Q51825431)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

lymphoblastic leukemia

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Giuseppe Basso

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Jacques Van Dongen

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

V H J Van der Velden

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

L Corral

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

M G Valsecchi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

M W J C Jansen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

P De Lorenzo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

G Cazzaniga

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

E R Panzer-Grümayer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

M Schrappe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

A Schrauder

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

C Meyer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

L L Nigro

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

M Metzler

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

G Mann

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

M L Den Boer

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

A Biondi

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

R Pieters

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Interfant-99 Study Group

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

12 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

1073-1079

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19212338%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2009.17

21 January 2020

exact match

0 references

cites work

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Towards targeted therapy for infant acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The 'big sister' of the infant disease?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leu

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Genomic DNA of leukemic patients: Target for clinical diagnosis ofMLL rearrangements

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Diagnostic tool for the identification of MLL rearrangements including unknown partner genes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Asymmetric multiplex-polymerase chain reaction - a high throughput method for detection and sequencing genomic fusion sites in t(4;11)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

BglII-based panhandle and reverse panhandle PCR approaches increase capability for cloning der(II) and der(other) genomic breakpoint junctions of MLL translocations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021

Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.17

7 January 2021